Table 5.
Historical comparison of outcomes in our study and the FACS study( 2 )
| FACS( 1 ) (n = 145) | This study (n = 98) | |
|---|---|---|
| Response rate (%) | 32 | 20 |
| Median PFS (months) | 4.5 | 4.8 |
| Median OS (months) | 12.3 | 16.5 |
| 1‐year survival rate (%) | 51 | 64 |
| Second‐line therapy, n (%) | 87 (60) | 76 (78) |
| Docetaxel | 25 (17) | 42 (43) |
| EGFR‐TKI | 9 (6) | 29 † (30) |
| Other | 58 (40) | 5 (5) |
†
25 patients were treated with Gefitinib. FACS, Four‐Arm Cooperative Study; PFS, progression‐free survival; EGFR‐TKI, epidermal growth factor receptor‐tyrosine kinase inhibitor.